NYSEAMERICAN:PLXProtalix Biotherapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Protalix Biotherapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.65 +0.11 (+3.11 %) (As of 08/14/2020 11:13 AM ET) Add Compare Share Today's Range$3.53Now: $3.65▼$3.6850-Day Range N/A52-Week Range$1.70Now: $3.65▼$4.86Volume2,119 shsAverage Volume189,785 shsMarket Capitalization$118.41 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which has completed phase IIa clinical trials for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is headquartered in Karmiel, Israel.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingProtalix Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Protalix Biotherapeutics has a potential upside of 206.4% from its current price of $3.59.Amount of Analyst CoverageProtalix Biotherapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesProtalix Biotherapeutics has received 223 “outperform” votes. (Add your “outperform” vote.)Underperform VotesProtalix Biotherapeutics has received 245 “underperform” votes. (Add your “underperform” vote.)Community SentimentProtalix Biotherapeutics has received 52.35% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Protalix Biotherapeutics and other stocks. Vote “Outperform” if you believe PLX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PLX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldProtalix Biotherapeutics does not currently pay a dividend.Dividend GrowthProtalix Biotherapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Protalix Biotherapeutics insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.18 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:PLX Previous SymbolNYSEMKT:PLX CUSIPN/A CIK1006281 Webwww.protalix.com Phone+972-4-9028100Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees184 Outstanding Shares32,442,000Market Cap$118.41 million Next Earnings Date11/5/2020 (Estimated) OptionableOptionable $3.65 +0.11 (+3.11 %) (As of 08/14/2020 11:13 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive PLX News and Ratings via Email Sign-up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter. Protalix Biotherapeutics (NYSEAMERICAN:PLX) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Protalix Biotherapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protalix Biotherapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Protalix Biotherapeutics. When is Protalix Biotherapeutics' next earnings date? Protalix Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Protalix Biotherapeutics. How were Protalix Biotherapeutics' earnings last quarter? Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) released its earnings results on Monday, August, 10th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.08. During the same quarter last year, the business earned ($0.50) EPS. View Protalix Biotherapeutics' earnings history. When did Protalix Biotherapeutics' stock split? How did Protalix Biotherapeutics' stock split work? Shares of Protalix Biotherapeutics reverse split on Friday, December 20th 2019. The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 19th 2019. An investor that had 100 shares of Protalix Biotherapeutics stock prior to the reverse split would have 10 shares after the split. What price target have analysts set for PLX? 1 brokerages have issued 12-month price objectives for Protalix Biotherapeutics' stock. Their forecasts range from $11.00 to $11.00. On average, they anticipate Protalix Biotherapeutics' stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 201.4% from the stock's current price. View analysts' price targets for Protalix Biotherapeutics. Has Protalix Biotherapeutics been receiving favorable news coverage? News articles about PLX stock have trended somewhat negative on Friday, according to InfoTrie. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Protalix Biotherapeutics earned a news impact score of -1.6 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news about Protalix Biotherapeutics. Are investors shorting Protalix Biotherapeutics? Protalix Biotherapeutics saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 195,800 shares, a decrease of 84.5% from the April 30th total of 1,260,000 shares. Based on an average daily volume of 200,300 shares, the days-to-cover ratio is presently 1.0 days. Currently, 0.8% of the shares of the stock are sold short. View Protalix Biotherapeutics' Short Interest. Who are some of Protalix Biotherapeutics' key competitors? Some companies that are related to Protalix Biotherapeutics include Inventiva (IVA), CEL-SCI (CVM), Pfenex (PFNX), Neptune Wellness Solutions (NEPT), IMV (IMV), Silence Therapeutics (SLN), TELIX Pharmaceutical (TLX), Starpharma (SPL), Synairgen (SNG), Ibio (IBIO), ProMetic Life Sciences (PLI), Fennec Pharmaceuticals (FRX), Verona Pharma (VRP), Ergomed (ERGO) and Rafael (RFL). View all competitors. What other stocks do shareholders of Protalix Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Protalix Biotherapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Pluristem Therapeutics (PSTI), Novavax (NVAX), BIOLINERX LTD/S (BLRX), VBI Vaccines (VBIV), Verastem (VSTM), Sangamo Therapeutics (SGMO), Biopharmx (BPMX), Opko Health (OPK) and Crispr Therapeutics (CRSP). Who are Protalix Biotherapeutics' key executives? Protalix Biotherapeutics' management team includes the following people: Mr. Moshe Manor, CEO, Pres & Director (Age 63)Dr. Yoseph Shaaltiel, Founder and Exec. VP R&D (Age 65)Mr. Yossi Maimon CPA, CPA, MBA, CFO, VP, Treasurer & Sec. (Age 48)Mr. Yaron Naos, Sr. VP of Operations (Age 55)Dr. Einat Brill-Almon, Sr. VP of Product Devel. (Age 59) What is Protalix Biotherapeutics' stock symbol? Protalix Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PLX." Who are Protalix Biotherapeutics' major shareholders? Protalix Biotherapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Psagot Investment House Ltd. (1.45%), Phoenix Holdings Ltd. (0.58%) and Bank of Montreal Can (0.54%). View institutional ownership trends for Protalix Biotherapeutics. Which major investors are buying Protalix Biotherapeutics stock? PLX stock was purchased by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd., Bank of Montreal Can, and Psagot Investment House Ltd.. View insider buying and selling activity for Protalix Biotherapeutics. How do I buy shares of Protalix Biotherapeutics? Shares of PLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Protalix Biotherapeutics' stock price today? One share of PLX stock can currently be purchased for approximately $3.65. How big of a company is Protalix Biotherapeutics? Protalix Biotherapeutics has a market capitalization of $118.41 million. Protalix Biotherapeutics employs 184 workers across the globe. What is Protalix Biotherapeutics' official website? The official website for Protalix Biotherapeutics is www.protalix.com. How can I contact Protalix Biotherapeutics? Protalix Biotherapeutics' mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The company can be reached via phone at +972-4-9028100. This page was last updated on 8/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
